KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC

BCG dosing for bladder cancer: Standard frequency schedule correct

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma

CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC

The future of cancer care in India

Choosing wisely: Lung adenocarcinoma

The changing landscape of cancer in India

Epidemiology of cancer in India

Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy

NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer

NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma